| |
Wednesday, May 14, 2025 | 11am ET / 8am PT Biotech success isn’t just about great science—it’s about building a compelling commercial narrative from day one. Join us to explore how early commercialization planning, powered by real-world insights, can maximize an asset’s potential. Our discussion will uncover strategies to integrate commercial thinking into R&D. Register now. 
|
|
Today’s Big NewsApr 28, 2025 |
| By Angus Liu Ending a 20-year-plus drought, Merck & Co.’s Keytruda showed that its use around surgery can reduce the risk of certain head and neck cancers from returning. While the drug stands to become a new standard of care, some questions remain. |
|
|
|
By Darren Incorvaia Dutch biotech Prilenia Therapeutics has entered a licensing pact with Spanish pharmaceutical company Ferrer to push the biotech's sole asset through clinical development and beyond in Europe. |
By Conor Hale Three Democrats called for an investigation into brain-computer interface devices, to make sure the data they collect is not simply sold for profit. |
By Kevin Dunleavy Merck KGaA’s long courtship of rare disease specialist SpringWorks Therapeutics has come to fruition as the German drugmaker has bought out the Connecticut biopharma for an equity value of $3.9 billion. |
|
Tuesday, May 6, 2025 | 9am ET / 6am PT This webinar will explore how to use AI-driven tools for timely data-driven decisions that are critical to securing approvals, expediting market entry and sustaining competitive strength. Register now. 
|
|
By Gabrielle Masson The Department of Health and Human Services has lifted a stop work order on Vaxart’s phase 2b trial testing out an investigational COVID-19 vaccine pill, with the biotech resuming plans to enroll participants for the 10,000-person study. |
By Conor Hale Ashley McEvoy will take over effective immediately as president and CEO from Jim Hollingshead, who has led Insulet since 2022. |
By Angus Liu As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD-(L)1xVEGF world, Akeso CEO Michelle Xia, Ph.D., figured that it’s high time the company recalibrated investors’ expectations. |
By Nick Paul Taylor The CEO of Novo Holdings has warned his $160 billion fund will slow down investment activity until the dust settles after the Trump administration’s tariff blitz. |
By Conor Hale According to the company, Hugo’s robotic assistance led to a 98.5% surgical success rate, alongside lower rates of serious complications when compared to historical averages. |
By Eric Sagonowsky Regeneron is off and running with its launch of linvoseltamab in Europe. In the U.S., the company is awaiting an FDA decision after last year's rejection. |
By Nick Paul Taylor Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes, with the Big Pharma finding no effect on overall survival and seeing a higher rate of serious adverse events in the PD-1 arm. |
By Conor Hale Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society, being held in San Diego this weekend. |
By Joseph Keenan Not letting up on the gas of its expansion efforts, PCI Pharma Services is picking up a 100% stake in the San Diego-based fill-finish CDMO Ajinomoto Althea, a subsidiary of Japan’s Ajinomoto. |
By Zoey Becker The latest data drop for tyrosine kinase inhibitor zongertinib reflects an "unparalleled" risk/benefit profile, Boehringer’s global head of oncology, SVP Itziar Canamasas, Ph.D., said. |
Fierce podcasts Don’t miss an episode |
| Two journalists, one name and a candid conversation—Angus Liu and Angus Chen talk cancer reporting, racial identity and being mistaken for each other. |
|
|---|
|
|
|
Tuesday, May 20, 2025 | 11am ET / 8am PT This webinar will feature industry experts discussing the power of combining biomedical data analysis with matched tissue and molecular samples. Register today to learn more. 
|
|
eBook Typical vaccine development timelines have averaged 10 years, but the time from the SARS-CoV-2 genetic sequence’s release to the submission of the first vaccine clinical trial data for regulatory review was a mere 314 days. In IQVIA Laboratories’ Vaccine eBook we focus on how contract research organizations (CROs) can best leverage strategic partnerships with sponsors to prepare for the next pandemic. Sponsored by: IQVIA |
Whitepaper Is your clinical trial data truly reliable? Learn how a combined approach using Imaging Core Labs and Endpoint Adjudication Committees (EAC) can minimize risk, control costs, and strengthen your study from the ground up. Don’t leave success to chance—arm yourself with the insights to stay ahead. Sponsored by: WCG |
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
